Ppt chapter 20-1

31
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Anxiolytic and Hypnotic Agents Chapter 20

description

 

Transcript of Ppt chapter 20-1

Page 1: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Anxiolytic and Hypnotic AgentsAnxiolytic and Hypnotic Agents

Chapter 20

Page 2: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Types of Anxiolytic and Hypnotic AgentsTypes of Anxiolytic and Hypnotic Agents

• Anxiolytics

– Prevent feelings of tension or fear

• Sedatives

– Calm and make patients unaware of the environment

• Hypnotics

– Cause sleep

• Minor Tranquilizers

– Produce a state of tranquility in anxious patients

Page 3: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Psychological States Affected by Anxiolytic and Hypnotic Drugs

Psychological States Affected by Anxiolytic and Hypnotic Drugs

• Anxiety

– Feeling of tension, nervousness, apprehension, or fear involving unpleasant reactions to a stimulus

• Sedation

– Loss of awareness and reaction to environmental stimuli

• Hypnosis

– Extreme sedation resulting in further CNS depression and sleep

Page 4: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Sites of Action of Benzodiazepines and Barbiturates and Other Anxiolytics

Sites of Action of Benzodiazepines and Barbiturates and Other Anxiolytics

Page 5: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Benzodiazepine: ActionBenzodiazepine: Action

• Act in the limbic system and the RAS

• Make GABA more effective

• Causes interference with neurons firing

• Lower doses cause anxiolytic effects

• Higher doses cause sedation and hypnosis

Page 6: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Benzodiazepine: IndicationsBenzodiazepine: Indications

• Anxiety disorders

• Alcohol withdrawal

• Hyperexcitability and agitation

• Preoperative relief of anxiety and tension

Page 7: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Benzodiazepine: PharmacokineticsBenzodiazepine: Pharmacokinetics

• Well absorbed from GI tract

• Peak levels achieved in 30 minutes to 2 hours

• Lipid soluble and distributes well throughout the body

• Cross placenta

• Enter breast milk

• Metabolized in the liver

• Excretion is primarily in the urine

Page 8: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Benzodiazepine: Contraindications and Cautions

Benzodiazepine: Contraindications and Cautions

• Allergy to benzodiazepine

• Psychosis

• Acute narrow angle glaucoma

• Shock

• Coma

• Acute alcohol intoxication

• Pregnancy

Page 9: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Benzodiazepine: Adverse EffectsBenzodiazepine: Adverse Effects

• Sedation

• Drowsiness

• Depression

• Lethargy

• Blurred Vision

• Confusion

• Dry Mouth

• Constipation

• Nausea

• Vomiting

• Hypotension

• Urinary Retention

Page 10: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Benzodiazepine: Drug-to-Drug Interactions

Benzodiazepine: Drug-to-Drug Interactions

• Increase CNS depression when taken with alcohol

• Increase in effect when taken with cimetidine, oral contraceptives, or disulfiram

• Decrease in effect if given with theophylline or ranitidine

Page 11: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

A client presents at the clinic with symptoms of hyperexcitability and agitation. Which medication would the nurse expect the physician to prescribe?

A. Hypnotic

B. Benzodiazepine

C. Barbiturate

D. Other Anxiolytic and Hypnotic Drugs

Page 12: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

B. Benzodiazepine

Rationale: Hyperexcitability and agitation are indications for the use of benzodiazepines.

Page 13: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

BarbituratesBarbiturates

• Act as a general CNS depressant

• Inhibit neuronal impulse conduction in the ascending RAS

• Depress the cerebral cortex

• Alter cerebellar function

• Depress motor output

Page 14: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Barbiturates: ActionBarbiturates: Action

• CNS depressants

• Inhibit neuroral impulse conduction in the ascending RAS

• Depress cerebral cortex

• Depress motor output

• Cause: sedation, hypnosis, anesthesia, and coma

Page 15: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Barbiturates: IndicationBarbiturates: Indication

• Relief of the signs and symptoms of anxiety

• Sedation

• Insomnia

• Preanesthesia

• Seizures

Page 16: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Barbiturates: Pharmacokinetics Barbiturates: Pharmacokinetics

• Well absorbed

• Reaching peak in 20 – 60 minutes

• Metabolized in the liver

• Excreted in the urine

Page 17: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Barbiturates: Contraindications and Cautions

Barbiturates: Contraindications and Cautions

• Allergy to any barbiturate

• Previous history of addiction to sedative–hypnotic drugs

• Latent or manifest porphyria

• Marked hepatic impairment or nephritis

• Respiratory distress or severe respiratory dysfunction

• Pregnancy

Page 18: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Barbiturates: Adverse ReactionsBarbiturates: Adverse Reactions

• CNS Depression

• Physical Dependency

• Drowsiness

• Somnolence

• Lethargy

• Ataxia

• Vertigo

• Nausea

• Vomiting

• Constipation

Page 19: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Barbiturates: Drug-to-Drug InteractionsBarbiturates: Drug-to-Drug Interactions

• Increase CNS depression when given with alcohol, antihistamines, and other tranquilizers

• Altered response to phenytoin

• MAO cause increase serum levels and effect

• Decrease effectiveness of the following drugs: anticoagulants, digoxin, tricyclic antidepressants, corticosteroids, oral contraceptive

Page 20: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

Please answer the following statement as true or false.

Peak levels of barbiturates occur in 60 to 90 minutes.

Page 21: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

False

Rationale: The barbiturates are absorbed well, reaching peak levels in 20 to 60 minutes.

Page 22: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Other Anxiolytic and Hypnotic DrugsOther Anxiolytic and Hypnotic Drugs

• Paraldehyde (Paral): Sedates patients with delirium tremens or psychiatric conditions characterized by extreme excitement

• Meprobamate (Miltown): Manages acute anxiety for up to 4 months

• Chloral Hydrate (Aquachloral): Produces nocturnal sedation or preoperative sedation

Page 23: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Other Anxiolytic and Hypnotic Drugs (cont.)

Other Anxiolytic and Hypnotic Drugs (cont.)

• Glutethimide (generic), zaleplon (Sonata), and zolpidem (Ambien): Short-term treatment of insomnia

• Antihistamines (promethazine [Phenergan], diphenhydramine [Benadryl]): Preoperative medications and postoperative to decrease the need for narcotics

• Buspirone (BuSpar): Reduces the signs and symptoms of anxiety without severe CNS and adverse effects

Page 24: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Use of Anxiolytic and Hypnotic Agents Across the Life Span

Use of Anxiolytic and Hypnotic Agents Across the Life Span

Page 25: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Benzodiazepines AgentPrototype Benzodiazepines Agent

Page 26: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Barbiturates AgentPrototype Barbiturates Agent

Page 27: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Barbiturates Agent (Continued)Prototype Barbiturates Agent (Continued)

Page 28: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Benzodiazepines

Nursing Considerations for Benzodiazepines

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 29: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Barbiturates Nursing Considerations for Barbiturates

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 30: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

You are admitting a new patient to the clinic. A review of home medications indicates the patient is taking a barbiturate to help him sleep. The patient tells you that he is having problems with both his visual and auditory senses. The patient wants to know what is wrong. What would be the best response?

A. We will have to wait and see what the doctor says.

B. What you are describing could be adverse effects from the sleep medicine you are taking.

C. There is nothing wrong. You are just getting older.

D. Sometimes these things happen with our patients. We need to do a complete assessment before we know for sure.

Page 31: Ppt chapter 20-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

B. What you are describing could be adverse effects from the sleeping medication you are taking?

Rationale: Nursing diagnoses related to drug therapy might include: Disturbed thought processes and disturbed sensory perception (visual, auditory, kinesthetic, tactile) related to CNS effects